Parkin depletion delays motor decline dose-dependently without overtly affecting neuropathology in α-synuclein transgenic mice

BMC Neuroscience

Volumn 14, Issue , 2013, Pages

  Fournier, Margot ^a,d,g   Roux, Amandine ^a,b,c   Garrigue, Jérôme ^a,b,c   Muriel, Marie Paule ^a,b,c   Blanche, Paul ^b   Lashuel, Hilal A ^d   Anderson, John P ^e   Barbour, Robin ^e   Huang, Jiping ^e   du Montcel, Sophie T ^b,f   Brice, Alexis ^a,b,c   Corti, Olga ^a,b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CNRS   (France)

^d EPFL   (Switzerland)

^e ELAN PHARMACEUTICALS   (United States)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

syn phosphorylation; syn truncation; parkin knockout mice; Parkinson's disease; Posttranslational modifications; Transgenic mice overproducing syn; Ubiquitin

Indexed keywords

ALPHA SYNUCLEIN; PARKIN; PROTEIN VARIANT; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; KNOCKOUT GENE; LEWY BODY; LONGITUDINAL STUDY; MOTOR DYSFUNCTION; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; SENSORIMOTOR FUNCTION; SENSORIMOTOR NEUROPATHY; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; ANIMALS; BLOTTING, WESTERN; BRAIN; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; MOTOR SKILLS; NERVE DEGENERATION; PARKINSON DISEASE; UBIQUITIN-PROTEIN LIGASES;

EID: 84887033337     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-14-135     Document Type: Article

References (43)

1. Oueslati A, Fournier M, Lashuel HA. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog Brain Res 2010, 183:115-145.
2. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006, 281(40):29739-29752. 10.1074/jbc.M600933200, 16847063.
3. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002, 4(2):160-164.
4. Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 2003, 278(45):44405-44411. 10.1074/jbc.M308041200, 12923179.
5. Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM, Trojanowski JQ, Mann D, Iwatsubo T. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem 2002, 277(50):49071-49076. 10.1074/jbc.M208046200, 12377775.
6. Sampathu DM, Giasson BI, Pawlyk AC, Trojanowski JQ, Lee VM. Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am J Pathol 2003, 163(1):91-100. 10.1016/S0002-9440(10)63633-4, 1868149, 12819014.
7. Rott R, Szargel R, Haskin J, Shani V, Shainskaya A, Manov I, Liani E, Avraham E, Engelender S. Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J Biol Chem 2008, 283(6):3316-3328.
8. Nonaka T, Iwatsubo T, Hasegawa M. Ubiquitination of alpha-synuclein. Biochemistry 2005, 44(1):361-368. 10.1021/bi0485528, 15628878.
9. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998, 152(4):879-884. 1858234, 9546347.
10. Campbell BC, McLean CA, Culvenor JG, Gai WP, Blumbergs PC, Jakala P, Beyreuther K, Masters CL, Li QX. The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J Neurochem 2001, 76(1):87-96.
11. Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, Dawson TM, Jakala P, Hartmann T, Price DL, et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A 2005, 102(6):2162-2167. 10.1073/pnas.0406976102, 548541, 15684072.
12. Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, Thomas PJ. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem 2005, 280(24):22670-22678. 10.1074/jbc.M501508200, 15840579.
13. Chen L, Periquet M, Wang X, Negro A, McLean PJ, Hyman BT, Feany MB. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 2009, 119(11):3257-3265. 2769182, 19855133.
14. Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, Ross CA, Dawson VL, Dawson TM. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 2001, 7(10):1144-1150. 10.1038/nm1001-1144, 11590439.
15. Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, Kirik D. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 2007, 130(Pt 3):799-815.
16. Fournier M, Vitte J, Garrigue J, Langui D, Dullin J-P, Saurini F, Hanoun N, Perez-Diaz F, Cornilleau F, Joubert C, et al. Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy. PLoS One 2009, 4(8):e6629. 10.1371/journal.pone.0006629, 2722082, 19680561.
17. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002, 34(4):521-533. 10.1016/S0896-6273(02)00682-7, 12062037.
18. Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 - > Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A 2002, 99(13):8968-8973. 10.1073/pnas.132197599, 124407, 12084935.
19. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. Alpha - synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A 2002, 99(16):10813-10818. 10.1073/pnas.152339799, 125054, 12122208.
20. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287(5456):1265-1269. 10.1126/science.287.5456.1265, 10678833.
21. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Muller V, Odoy S, Fujiwara H, Hasegawa M, et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 2002, 110(10):1429-1439. 151810, 12438441.
22. Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T. Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci 2011, 31(46):16884-16894. 10.1523/JNEUROSCI.3967-11.2011, 22090514.
23. van der Putten H, Wiederhold KH, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren WP, Ruegg MA, et al. Neuropathology in mice expressing human alpha-synuclein. J Neurosci 2000, 20(16):6021-6029.
24. Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem 2004, 91(2):451-461. 10.1111/j.1471-4159.2004.02728.x, 15447678.
25. Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev 2011, 91(4):1161-1218. 10.1152/physrev.00022.2010, 22013209.
26. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denefle P, Wood NW, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000, 342(21):1560-1567. 10.1056/NEJM200005253422103, 10824074.
27. Dawson TM, Dawson VL. The role of parkin in familial and sporadic Parkinson's disease. Mov Disord 2010, 25(Suppl 1):S32-39.
28. Haywood AF, Staveley BE. Parkin counteracts symptoms in a Drosophila model of Parkinson's disease. BMC Neurosci 2004, 5:14. 10.1186/1471-2202-5-14, 419346, 15090075.
29. Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, Choi P, Wolozin B, Farrer M, Hardy J, et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002, 36(6):1007-1019. 10.1016/S0896-6273(02)01125-X, 12495618.
30. Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 2003, 37(6):911-924. 10.1016/S0896-6273(03)00143-0, 12670421.
31. von Coelln R, Thomas B, Andrabi SA, Lim KL, Savitt JM, Saffary R, Stirling W, Bruno K, Hess EJ, Lee MK, et al. Inclusion body formation and neurodegeneration are parkin-independent in a mouse model of alpha-synucleinopathy. J Neurosci 2006, 26(14):3685-3696. 10.1523/JNEUROSCI.0414-06.2006, 16597723.
32. Kahle PJ, Neumann M, Ozmen L, Muller V, Odoy S, Okamoto N, Jacobsen H, Iwatsubo T, Trojanowski JQ, Takahashi H, et al. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 2001, 159(6):2215-2225. 10.1016/S0002-9440(10)63072-6, 1850592, 11733371.
33. Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, Laville M, Pratt J, Corti O, Pradier L, et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 2003, 12(18):2277-2291. 10.1093/hmg/ddg239, 12915482.
34. Vitte J, Traver S, Maues De Paula A, Lesage S, Rovelli G, Corti O, Duyckaerts C, Brice A. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease. J Neuropathol Exp Neurol 2010, 69(9):959-972. 10.1097/NEN.0b013e3181efc01c, 20720502.
35. Jan C, Muriel MP, Rolland AS, Hirsch EC, Francois C. Localization of D1a dopamine receptors on cell bodies and axonal endings in the substantia nigra pars reticulata of the rat. J Neural Transm 2007, 114(12):1509-1517. 10.1007/s00702-007-0775-8, 17576511.
36. Thingholm TE, Larsen MR. The use of titanium dioxide micro-columns to selectively isolate phosphopeptides from proteolytic digests. Methods Mol Biol 2009, 527:57-66. xi, 10.1007/978-1-60327-834-8_5, 19241005.
37. Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, Fournier M, Olschewski D, Yin G, Zweckstetter M, Masliah E, et al. Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem 2010, 285(4):2807-2822. 10.1074/jbc.M109.081950, 2807335, 19889641.
38. Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, Fredenburg RA, Lansbury PT, Fernandez CO, Eliezer D, Zweckstetter M, et al. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem 2008, 283(24):16895-16905. 10.1074/jbc.M800747200, 2423264, 18343814.
39. Inglis KJ, Chereau D, Brigham EF, Chiou SS, Schobel S, Frigon NL, Yu M, Caccavello RJ, Nelson S, Motter R, et al. Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem 2009, 284(5):2598-2602. 2631975, 19004816.
40. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 2001, 21(24):9549-9560.
41. Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, Tanzi RE, Sawa A, LD V, Dawson TM, Ross CA. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 2001, 10(9):919-926. 10.1093/hmg/10.9.919, 11309365.
42. Lewis KA, Yaeger A, DeMartino GN, Thomas PJ. Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations. J Bioenerg Biomembr 2010, 42(1):85-95. 10.1007/s10863-009-9258-y, 3266686, 20148295.
43. Choubey V, Safiulina D, Vaarmann A, Cagalinec M, Wareski P, Kuum M, Zharkovsky A, Kaasik A. Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem 2011, 286(12):10814-10824. 10.1074/jbc.M110.132514, 3060532, 21252228.